Start with the mildest cases in the EHS Global Census 2025 — those participants who scored in the lowest symptom range — and women represent about 62% of that group. That proportion is roughly what you’d expect given that women make up 74% of census enrollment overall. It’s slightly lower than average representation, actually.
Now move up through the severity categories. As scores rise through possible electrosensitivity and into intermittent cases, the female percentage holds steady in that same 59–62% range. Nothing dramatic.
Then something changes.
At the Electro-Sensitivity tier, where symptom scores climb into the range that meaningfully disrupts daily function, female representation jumps to 78%. And at the top of the scale, among participants meeting full Electrohypersensitivity criteria, women represent 88% of cases. Thirty women, four men.
That is not noise. That is not a sampling artifact. That is a gradient, and gradients tell stories that flat differences cannot.
What the Pattern Itself Rules Out
When researchers encounter gender differences in health data, the first question is usually: are we measuring a real difference in burden, or a real difference in reporting? Women are more likely, on average, to seek healthcare, to discuss symptoms, to complete questionnaires. Could the 88% simply reflect who bothers to fill out surveys?
The gradient answers that question directly.
If women in this sample were reporting symptoms they don’t actually experience, we’d see consistent overrepresentation across all severity categories. But that isn’t what we find. In the mildest cases, women are slightly underrepresented relative to overall enrollment. The gender gap widens only as severity climbs. Reporting tendency doesn’t amplify selectively at high scores. Biology does.
The mean symptom score difference reinforces this. Across the full Survey B sample of 141 participants, women scored an average of 85.3 out of 250, compared to 61.8 for men, a 38% higher burden, statistically significant at p=0.005. Women aren’t just more numerous in the census; they are measurably sicker, and the gap between them grows as the condition becomes more severe.
Something biological is happening here. The gradient demands an explanation.
The Hormonal Architecture of Sensitivity
The most immediate candidate is the hormonal system, and for good reason. Estrogen and progesterone aren’t peripheral players in neurological function; they’re central to how the nervous system regulates itself, responds to stress, and manages inflammatory signals.
Estrogen, in particular, modulates the autonomic nervous system in ways that affect how the body responds to environmental stimuli. It influences mast cell activation, histamine metabolism, and inflammatory tone. It shapes the brain’s response to sensory input, adjusting thresholds in ways that shift across the menstrual cycle and change substantially during perimenopause and menopause. Sleep architecture, too, is tightly coupled to hormonal status: progesterone promotes deeper, more restorative sleep, and its decline during perimenopause is one of the earliest and most reliably documented contributors to sleep disruption.
This matters enormously for EHS, because sleep is where the condition shows up first and most powerfully. Across the census, sleep disruption correlated with symptom severity at r=0.638, explaining over 40% of the variance in how sick participants were. The direct correlation between EMF exposure and symptoms, by comparison, was r=0.413. Sleep is the bottleneck through which environmental stress translates into physical suffering, and the hormonal system is one of the primary regulators of sleep quality.
A woman navigating perimenopause is contending with a hormonal environment already destabilizing her sleep. If artificial EMF exposure adds to that disruption, even modestly, the combined effect on her sleep architecture may be disproportionate, pushing her toward non-restorative sleep patterns that men with similar exposure levels don’t experience. The same underlying exposure produces different downstream effects depending on the hormonal substrate it lands on.
The 31–45 age group, which shows the highest symptom burden in the census (mean score 91.6, compared to 58.0 in the 18–30 group), is also the window during which hormonal transitions begin for many women. That overlap is unlikely to be coincidental.
The Sleep Connection in Women
Survey C, which assessed sleep disorders among 113 census participants, adds considerable texture to this picture.
Women comprise 82.7% of the Moderate sleep dysfunction category in Survey C, despite representing 71.7% of the overall sample. That’s a disproportionate burden even relative to female overrepresentation. And when sleep dysfunction manifests in women, it manifests differently than in men.
Factor analysis of Survey C responses identified two distinct dimensions of sleep disruption: Daytime Functional Impairment (fatigue, concentration problems, mood changes, physical pain) and Sleep Initiation and Maintenance Anxiety (worry about sleep, difficulty falling asleep, night awakenings). Women scored significantly higher than men on Daytime Functional Impairment, with a factor score mean of 0.118 versus -0.299, statistically significant at p=0.030. On Sleep Anxiety, there was no meaningful gender difference.
What this means practically: women in this sample aren’t just having more difficulty falling asleep. Their sleep, when it occurs, is less restorative, and the next day carries a heavier functional cost. Fatigue deeper. Concentration more impaired. Physical symptoms more pronounced. This is the pattern of sleep that’s occurring but failing to perform its regenerative work, and women appear to experience that failure more acutely.
The secondary sleep disorder data sharpens the picture further. Among women in Survey C, 37.5% reported vivid dreams or sleep paralysis, compared to 15.6% of men, more than double. Nearly half of women (48.1%) reported bruxism, the teeth grinding that signals a nervous system remaining partially activated through sleep rather than achieving the parasympathetic rest it needs to recover. Restless legs syndrome was also more prevalent in women (29.6% versus 25.0%), and this matters clinically because RLS is linked to iron metabolism, specifically to ferritin levels that are often technically “normal” but functionally insufficient, a pattern more common in women due to menstrual blood loss.
These aren’t coincidental comorbidities. They’re different expressions of a sleep system under stress, one that women, for reasons rooted in biology, appear more vulnerable to.
The Neighborhood of Overlapping Conditions
EHS doesn’t exist in isolation, and understanding the gender gradient requires looking at where it sits in the broader map of female-predominant conditions.
Fibromyalgia affects women in roughly 80–90% of cases. Chronic fatigue syndrome shows 75–80% female prevalence. Multiple chemical sensitivity runs at 70–80% female. Mast cell activation syndrome (MCAS) is predominantly female. These are not diseases caused by fragility or excessive health awareness. They are conditions involving dysregulated inflammatory signaling, autonomic dysfunction, and altered sensitivity to environmental stimuli, and they cluster in women at rates that demand a biological explanation.
EHS shares significant clinical overlap with all of them. The sensitivity clustering finding from the census is relevant here: 76% of EHS participants reported environmental sensitivities beyond artificial EMF, including reactions to noise, scent, light, food additives, and seasonal changes. The sensitivity profile of someone with EHS often resembles that of someone with MCAS or multiple chemical sensitivity, and the underlying mechanisms, involving mast cell reactivity and histamine metabolism, show strong female predominance.
This clustering isn’t a complication to be explained away. It’s a clue. It suggests these conditions may share biological soil: a terrain characterized by heightened immune reactivity, autonomic dysregulation, and higher sensitivity to artificial environmental exposures that a less reactive system might tolerate. Women, statistically, are more likely to occupy that terrain. Why remains an active question in research. The answer, when it comes, will probably have something to do with estrogen’s role in immune priming and the ways hormonal variability amplifies environmental sensitivity thresholds.
Exposure Patterns Matter Too
Beyond biology, it’s worth examining where people actually spend their time.
Occupational exposure studies have historically focused on industrial and technology environments, which skewed male in earlier decades. Domestic exposure, from WiFi routers running through the night, from smart meters on bedroom walls, from phones charged at bedsides, has received less systematic attention, and domestic environments are ones where women have historically spent more time.
This is a blunt observation and not a deterministic one. But if the bedroom is the highest-leverage artificial EMF exposure environment, which the census sleep data strongly suggests, then any pattern of domestic exposure warrants attention alongside occupational exposure. The census documented that 60.8% of all participants keep phones active and accessible during sleep, 37.4% charge phones beside the bed, and 23.3% sleep with phones under their pillow or very close. These are habits that cut across gender, but their consequences may not land equally.
What “Dismissed” Actually Costs
There is a harder context for these numbers, one that doesn’t require data to recognize.
Women’s health symptoms have a long history of being attributed to anxiety, psychosomatic patterns, or heightened emotional sensitivity rather than physical causes. Conditions that primarily affect women, from endometriosis to fibromyalgia to autoimmune disorders, have consistently faced longer diagnostic delays, more frequent misattribution, and less research funding than conditions with comparable male prevalence.
EHS is, in this sense, a familiar story. The symptoms are real, they’re invisible to external observation, and they cluster in women who are already navigating systems not designed to take their complaints seriously. The gradient finding, not just that women have higher rates but that women dominate increasingly as severity rises, provides something concrete: measurable evidence that this isn’t an artifact of how women talk about their health, but a quantifiable biological reality.
That matters clinically. A woman presenting with EHS, especially in the 31–45 age group and especially with moderate-to-severe symptom burden, deserves a thorough evaluation rather than reassurance. Her hormonal status is worth investigating. Overlapping conditions, MCAS, fibromyalgia, histamine intolerance, warrant screening rather than assumption. The high rates of vivid dreams and sleep paralysis in the census suggest REM dysregulation that deserves attention beyond lifestyle advice. And the statistically significant daytime impairment burden means her functional capacity the following day is genuinely compromised in ways that matter to her work, her relationships, and her ability to manage her own recovery.
What the Research Needs to Answer
The gradient finding is a destination marker, not an explanation. It tells us where to look, not yet why.
Hormonal mechanisms warrant systematic investigation, specifically how estrogen and progesterone fluctuation interacts with autonomic sensitivity to artificial EMF exposure, and whether hormonal transitions like perimenopause represent inflection points in EHS progression. The age distribution data from the census, with its pronounced 31–45 peak, makes this question more urgent.
The overlap with female-predominant inflammatory and immunological conditions needs study that goes beyond observation. If mast cell activation and histamine dysregulation are genuine mediating mechanisms, then the female predominance in EHS may be partly explained by the same biology that drives MCAS, and targeted interventions addressing histamine tolerance and mast cell reactivity could become part of clinical management for severely affected women.
Gender-stratified analysis should also become standard in EHS research, not a subset analysis added post hoc. The census data makes clear that men and women are experiencing this condition differently, not just in prevalence but in which symptoms dominate, how sleep disruption manifests, and where in the severity spectrum they concentrate. A single undifferentiated analysis obscures those differences.
The 88 Percent
Start, again, with mild cases. Women at 62%. Move through the categories, watching that number climb (59, 62, 78, 88) and what you’re watching is a biological signal accumulating strength as the underlying condition becomes more severe. That’s not a cohort composition artifact. That’s the immune system, the hormonal system, and the autonomic nervous system converging on an outcome that looks, from the outside, like an unfortunate statistical pattern but is, in lived experience, a woman whose sleep is failing to restore her, whose days carry a weight her male counterpart does not feel, and whose complaints are all too often filed under something other than what they are.
The 88% finding isn’t incidental. Understanding why it exists could reveal mechanisms relevant to every person living with EHS, regardless of gender. And the women it describes deserve the recognition that their experience is not imagined, not amplified by sensitivity of temperament, but measurably, biologically distinct, and worthy of the scientific attention it has long been denied.
This article examines the gender gap findings in the EHS Global Census. For complete prevalence data, correlation analyses, and integration with other census findings, the full technical reports are available at 2025 EHSGC Reports.